iSpecimen Inc.
iSpecimen Inc. (ISPC) Financial Performance & Income Statement Overview
Access detailed quarterly and annual financial reports for iSpecimen Inc. (ISPC), covering cash flow, earnings, and balance sheets.
iSpecimen Inc. (ISPC) Income Statement & Financial Overview
Analyze iSpecimen Inc.’s ISPC earnings with segmented quarterly and yearly financial statement figures.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $1.06M | $1.48M | $2.66M | $2.86M |
| Cost of Revenue | $657279.00 | $1.32M | $1.55M | $2.03M |
| Gross Profit | $400231.00 | $151352.00 | $1.11M | $832543.00 |
| Gross Profit Ratio | $0.38 | $0.10 | $0.42 | $0.29 |
| R&D Expenses | $545367.00 | $951667.00 | $0.00 | $1.05M |
| SG&A Expenses | $1.11M | $6.22M | $1.52M | $2.57M |
| Operating Expenses | $2.04M | $5.99M | $2.81M | $3.01M |
| Total Costs & Expenses | $2.70M | $7.32M | $4.37M | $5.05M |
| Interest Income | $2788.00 | $3237.00 | $1235.00 | $9163.00 |
| Interest Expense | $20486.00 | $203771.00 | $7364.00 | $4474.00 |
| Depreciation & Amortization | $432709.00 | $548036.00 | $542779.00 | $606744.00 |
| EBITDA | -$1.21M | -$5.30M | -$889710.00 | -$1.50M |
| EBITDA Ratio | -$1.14 | -$3.59 | -$0.33 | -$0.52 |
| Operating Income | -$1.64M | -$5.84M | -$1.71M | -$2.18M |
| Operating Income Ratio | -$1.55 | -$3.96 | -$0.64 | -$0.76 |
| Other Income/Expenses (Net) | -$20007.00 | -$206355.00 | $265551.00 | $72641.00 |
| Income Before Tax | -$1.66M | -$6.05M | -$1.44M | -$2.11M |
| Income Before Tax Ratio | -$1.57 | -$4.10 | -$0.54 | -$0.74 |
| Income Tax Expense | $0.00 | $0.00 | $0.00 | -$4.00 |
| Net Income | -$1.66M | -$6.05M | -$1.44M | -$2.11M |
| Net Income Ratio | -$1.57 | -$4.10 | -$0.54 | -$0.74 |
| EPS | -$2.33 | -$8.51 | -$2.10 | -$3.72 |
| Diluted EPS | -$2.33 | -$8.51 | -$2.10 | -$3.72 |
| Weighted Avg Shares Outstanding | $710852.00 | $710852.00 | $687141.00 | $567029.00 |
| Weighted Avg Shares Outstanding (Diluted) | $710852.00 | $710852.00 | $687141.00 | $567029.00 |
Over the past four quarters, iSpecimen Inc. demonstrated steady revenue growth, increasing from $2.86M in Q2 2024 to $1.06M in Q1 2025. Operating income reached -$1.64M in Q1 2025, maintaining a consistent -155% margin over recent quarters. Despite fluctuations in R&D and SG&A expenses, EBITDA remained robust at -$1.21M, reflecting operational efficiency. Net income rose to -$1.66M, with EPS at -$2.33. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan